{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-173043","form_type":"8-K","ticker":"SNSE","cik":"0001829802","company_name":"Sensei Biotherapeutics, Inc.","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.199214+00:00","generated_at":"2026-05-17T20:58:48.096135+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Sensei Biotherapeutics Q2 net loss $4.9M; cash runway into Q2 2026; Phase 1/2 data year-end","bullets":["Cash, cash equivalents and marketable securities $28.6M at June 30, 2025 (down from $41.3M at Dec 31, 2024).","Net loss $4.9M for Q2 2025 vs $7.1M for Q2 2024; R&D expenses decreased to $2.5M from $4.6M.","Phase 1/2 dose expansion cohort enrollment complete (64 patients); full data including 6-month PFS expected by year-end 2025.","Data to be presented at ESMO Congress 2025 (Oct 17-21) in a mini oral session.","Regained Nasdaq compliance after 1-for-20 reverse split effective June 16, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-173043","json":"https://secwatch.observer/filing/0001193125-25-173043.json","markdown":"https://secwatch.observer/filing/0001193125-25-173043.md","text":"https://secwatch.observer/filing/0001193125-25-173043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829802/000119312525173043/0001193125-25-173043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829802/000119312525173043/d46736d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:58:48.096135+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}